stockrow
Saturday 7 November 2026
Export WVE’s income statement to Excel — free account
WAVE Life Sciences Ltd.
WAVE Life Sciences Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42.7 million, down 60.5% from fiscal 2024.
- Revenue
- +73.0%
- EPS
- +5.25%
- Free cash flow
- −33.9%
Quarter to September 2026, against a year earlier
3.36
0.14
+4.35%
Follow WVE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
10.65 | 18.13 | 20.21 | 67.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(12.56) | (22.12) | (24.37) | (84.88) | |
P/B ratio |
1.88 | 2.61 | 2.84 | 5.53 | |
Price to Tangible BV |
1.88 | 2.61 | 2.84 | 5.53 | |
EV/Sales |
4.58 | 10.63 | 12.63 | 53.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.57) | (3.63) | (4.93) | (12.08) | |
EV/FCF |
(1.56) | (3.60) | (4.90) | (12.03) | |
Quick Ratio |
8.09 | 9.67 | 10.93 | 6.35 | |
Current Ratio |
8.38 | 9.99 | 11.26 | 6.47 | |
Net Debt/EBITDA |
6.76 | 6.87 | 18.78 | 11.11 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.19 | 0.16 | 0.16 | 0.09 | |
Operating CF/Net income |
0.97 | 0.77 | 2.28 | 0.64 | |
Capex/Depreciation |
(0.01) | (0.37) | (0.19) | 0.00 | |
Research and Development Expense of Revenue |
409.20% | 2,257.61% | 124.04% | 306.26% | |
Selling, General and Administrative Expense of Revenue |
192.75% | 1,090.71% | 57.79% | 121.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
78.19% | 472.40% | 23.70% | 42.63% | |
Graham Net Nets |
0.47 | 0.34 | 0.34 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(29.01%) | (18.76%) | (14.62%) | (7.18%) | |
Free Cash Flow Yield |
(27.58%) | (16.30%) | (12.75%) | (6.56%) | |
Revenue per Share |
0.06 | 0.01 | 0.19 | 0.10 | |
Operating CF per Share |
(0.29) | (0.26) | (0.30) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.29) | (0.27) | (0.30) | (0.20) | |
Cash per Share |
2.11 | 2.40 | 2.72 | 3.57 | |
Shareholders Equity per Share |
1.97 | 2.22 | 2.56 | 3.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.97 | 2.22 | 2.56 | 3.07 | |
Free Cash Flow |
(60.16) | (54.47) | (59.99) | (33.77) | |
Working Capital |
403.87 | 456.69 | 511.44 | 519.75 | |
Capital Expenditures |
(0.01) | (0.88) | (0.44) | 0.00 | |
Net Current Asset Value |
352.64 | 402.71 | 489.46 | 494.67 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.39 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.81 | 1.16 | — | 1.28 | |
Average Payables |
16.89 | 17.51 | 16.71 | 15.98 | |
Average Assets |
374.65 | 405.34 | 435.94 | 495.35 | |
Average Common Equity |
263.24 | 296.39 | 341.77 | 363.94 |
Columns are period end dates · fundamentals updated 2 Nov 2026